Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Nanobiotix and Weill Cornell Medicine Partner on Pre-Clinical Research Inbox x

Abstract:
NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today that it is launching a research collaboration with Weill Cornell Medicine to begin nonclinical studies of NBTXR3’s mechanism of action. NBTXR3 is a first-in-class product designed to destroy, when activated by radiotherapy, tumors and metastasis through physical cell death and to induce immunogenic cell death leading to specific activation of the immune system.

Nanobiotix and Weill Cornell Medicine Partner on Pre-Clinical Research Inbox x

Paris, France and Cambridge, MA | Posted on May 3rd, 2018

The research collaboration between Weill Cornell Medicine, based in New York City, and Nanobiotix will be conducted over the course of one year, with the goal of continuing the exploration of the role of NBTXR3 in Immuno-Oncology.

The main objective of this collaboration is to study the impact of NBTXR3 activated by radiotherapy on the cGAS-STING pathway using different in vitro and in vivo murine models (mammary). Along with immunogenic cell death, the cGAS-STING pathway has emerged as the key component of the anti-tumor immune response. Data generated from this collaboration could support current evidence indicating that NBTXR3 activated by radiotherapy can increase the anti-tumor immune response, compared with radiotherapy alone, and transform an irradiated tumor into an efficient in situ vaccine.

Dr. Sandra Demaria, M.D., Professor of Radiation Oncology and Chief of the Division of Experimental Radiotherapy in the Department of Radiation Oncology at Weill Cornell Medicine, and Principal Investigator for the study, said: “We have learned that radiotherapy has the potential to convert a tumor into an in-situ vaccine, and enhance systemic tumor responses to immunotherapy. But there is room for improvement: NBTXR3 nanoparticles enhance the pro-immunogenic effects of radiotherapy, and we want to understand how they work. This knowledge will further the development of this innovative approach for the treatment of cancer patients who are resistant to immune checkpoint inhibitors.”

The Company received the FDA’s approval to launch a clinical study of NBTXR3 activated by radiotherapy in combination with anti-PD1 antibody in lung, and head and neck cancer patients (head and neck squamous cell carcinoma and nonsmall cell lung cancer). This trial that shall start in Q2 2018, aims to expand the potential of NBTXR3, including using it to treat recurrent or metastatic disease.

NBTXR3 positioning in IO
Many IO combination strategies focus on ‘priming’ the tumor, which is now becoming a prerequisite of turning a “cold” tumor into a “hot” tumor.

Compared to other modalities that could be used for priming the tumor, NBTXR3 could have a number of advantages: the physical and universal mode of action that could be used widely across oncology, a one-time local injection and good fit within existing medical practice already used as a basis for cancer treatment, as well as a very good chronic safety profile and well-established manufacturing process.

Published preclinical and clinical data indicate that NBTXR3 could play a key role in oncology and could become a backbone in immuno-oncology.
Nanobiotix’s immuno-oncology combination program opens the door to new developments, potential new indications, and important value creation opportunities.

-ends-


About NBTXR3
NBTXR3 is a first-in-class product designed to destroy, when activated by radiotherapy, tumors and metastasis through physical cell death and to immunogenic cell death leading to specific activation of the immune system.

NBTXR3 has a high degree of biocompatibility, requires one single administration before the whole radiotherapy treatment and has the ability to fit into current worldwide standards of radiation care.

NBTXR3 is being evaluated in head and neck cancer (locally advanced squamous cell carcinoma of the oral cavity or oropharynx), and the trial targets frail and elderly patients who have advanced cancer with very limited therapeutic options. The Phase I/II trial has already delivered very promising results regarding the local control of the tumors and a potential metastatic control through in situ vaccination.

Nanobiotix is running an Immuno-Oncology program with NBTXR3 that includes several studies. In the U.S., the Company received the FDA’s approval to launch a clinical study of NBTXR3 activated by radiotherapy in combination with anti-PD1 antibodies in lung, and head and neck cancer patients (head and neck squamous cell carcinoma and non-small cell lung cancer). This trial aims to expand the potential of NBTXR3, including using it to treat recurrent or metastatic disease.

The first market authorization process (CE Marking) is ongoing in Europe in the soft tissue sarcoma indication.

The other ongoing studies are treating patients with liver cancers (hepatocellular carcinoma and liver metastasis), locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma.

####

About Nanobiotix
Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is one rooted in designing pioneer physical based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges.

The Company’s first-in-class, proprietary lead technology, NanoXray, aims to expand radiotherapy benefits for millions of cancer patients. Furthermore, the Company’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s Headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA, and european affiliates in Spain and Germany.


For more information, please click here

Contacts:
Nanobiotix

Sarah Gaubert
Director, Communication & Public Affairs
+33 (0)1 40 26 07 55
/




Noël Kurdi
Director, Investor Relations
+1 (646) 241-4400
/
Media relations

France - Springbok Consultants
Marina Rosoff
+33 (0)6 71 58 00 34



United States – RooneyPartners
Marion Janic
+1 (212) 223-4017

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Synopsys and GLOBALFOUNDRIES Collaborate to Develop Industry’s First Automotive Grade 1 IP for 22FDX Process: Synopsys’ Portfolio of DesignWare Foundation, Analog, and Interface IP Accelerate ISO 26262 Qualification for ADAS, Powertrain, 5G, and Radar Automotive SoCs February 22nd, 2019

With nanopore sensing, VCU physics researchers detect subtle changes in single particles: The researchers' findings 'open the door to observe all kinds of interesting phenomenon on nanosurfaces,' an area of great interest to chemists February 21st, 2019

Platinum nanoparticles for selective treatment of liver cancer cells February 21st, 2019

What happens to magnetic nanoparticles once in cells? February 21st, 2019

Cancer

With nanopore sensing, VCU physics researchers detect subtle changes in single particles: The researchers' findings 'open the door to observe all kinds of interesting phenomenon on nanosurfaces,' an area of great interest to chemists February 21st, 2019

Platinum nanoparticles for selective treatment of liver cancer cells February 21st, 2019

Possible Futures

Synopsys and GLOBALFOUNDRIES Collaborate to Develop Industry’s First Automotive Grade 1 IP for 22FDX Process: Synopsys’ Portfolio of DesignWare Foundation, Analog, and Interface IP Accelerate ISO 26262 Qualification for ADAS, Powertrain, 5G, and Radar Automotive SoCs February 22nd, 2019

With nanopore sensing, VCU physics researchers detect subtle changes in single particles: The researchers' findings 'open the door to observe all kinds of interesting phenomenon on nanosurfaces,' an area of great interest to chemists February 21st, 2019

Platinum nanoparticles for selective treatment of liver cancer cells February 21st, 2019

What happens to magnetic nanoparticles once in cells? February 21st, 2019

Nanomedicine

With nanopore sensing, VCU physics researchers detect subtle changes in single particles: The researchers' findings 'open the door to observe all kinds of interesting phenomenon on nanosurfaces,' an area of great interest to chemists February 21st, 2019

Platinum nanoparticles for selective treatment of liver cancer cells February 21st, 2019

What happens to magnetic nanoparticles once in cells? February 21st, 2019

Sensitive sensor detects Down syndrome DNA February 14th, 2019

Announcements

Synopsys and GLOBALFOUNDRIES Collaborate to Develop Industry’s First Automotive Grade 1 IP for 22FDX Process: Synopsys’ Portfolio of DesignWare Foundation, Analog, and Interface IP Accelerate ISO 26262 Qualification for ADAS, Powertrain, 5G, and Radar Automotive SoCs February 22nd, 2019

With nanopore sensing, VCU physics researchers detect subtle changes in single particles: The researchers' findings 'open the door to observe all kinds of interesting phenomenon on nanosurfaces,' an area of great interest to chemists February 21st, 2019

Platinum nanoparticles for selective treatment of liver cancer cells February 21st, 2019

What happens to magnetic nanoparticles once in cells? February 21st, 2019

Nanobiotechnology

With nanopore sensing, VCU physics researchers detect subtle changes in single particles: The researchers' findings 'open the door to observe all kinds of interesting phenomenon on nanosurfaces,' an area of great interest to chemists February 21st, 2019

Platinum nanoparticles for selective treatment of liver cancer cells February 21st, 2019

What happens to magnetic nanoparticles once in cells? February 21st, 2019

Sensitive sensor detects Down syndrome DNA February 14th, 2019

Alliances/Trade associations/Partnerships/Distributorships

Synopsys and GLOBALFOUNDRIES Collaborate to Develop Industry’s First Automotive Grade 1 IP for 22FDX Process: Synopsys’ Portfolio of DesignWare Foundation, Analog, and Interface IP Accelerate ISO 26262 Qualification for ADAS, Powertrain, 5G, and Radar Automotive SoCs February 22nd, 2019

CEA-Leti & Stanford Target Edge-AI Apps with Breakthrough Memory Cell: Paper at ISSCC 2019 Presents Proof-of-Concept Multi-Bit Chip That Overcomes NVM’s Read/Write, Latency and Integration Challenges February 20th, 2019

John Chong of Kionix Named Chair of MEMS & Sensors Industry Group Governing Council February 6th, 2019

TOCHA will take a topological approach to the next generation of electronic, photonic and phononic devices January 31st, 2019

Research partnerships

Synopsys and GLOBALFOUNDRIES Collaborate to Develop Industry’s First Automotive Grade 1 IP for 22FDX Process: Synopsys’ Portfolio of DesignWare Foundation, Analog, and Interface IP Accelerate ISO 26262 Qualification for ADAS, Powertrain, 5G, and Radar Automotive SoCs February 22nd, 2019

CEA-Leti & Stanford Target Edge-AI Apps with Breakthrough Memory Cell: Paper at ISSCC 2019 Presents Proof-of-Concept Multi-Bit Chip That Overcomes NVM’s Read/Write, Latency and Integration Challenges February 20th, 2019

Exotic spiraling electrons discovered by physicists: Rutgers-led research could lead to advances in lighting and solar cells February 18th, 2019

Laser-induced graphene gets tough, with help: Rice University lab combines conductive foam with other materials for capable new composites February 12th, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project